Skip to main content

Table 7 aliskren monotherapy and renal effects for patients who are suffered from hypertension and diabetes and/or nephropathy or albuminuria at the same time

From: Clinical efficacy, safety and tolerability of Aliskiren Monotherapy (AM): an umbrella review of systematic reviews

AuthorIndicationTotal Sample SizeFollow upDrug ComparisonPrimary Outcome - Results
Evangelos C. Rizos, Aris P. Agouridis and Moses S.Elisafnon-diabetic chronic kidney disease1442placebo vs. aliskiren 300 mg vs. perindopril 10 mgUPER: −36% for aliskiren and − 25% for perindopril 10 mg
Both treatments vs. placebo: p < 0.05
 IgA nephropathy2236placebo vs. aliskiren 300 mgReduction in UPCR (g/g)
 T2DM and hypertension and albuminuria26 (crossover design)4 × 2-monthsPlacebo vs. aliskiren300mg vs. irbesartan 300 mgUAER: −48% for aliskiren and − 51% for irbesartan
Both treatments vs. placebo: p < 0.001
 T2DM and hypertension and albuminuria26 (crossover design)4 × 2-months150 or 300 or 600 mg aliskiren vs. placeboUAER: −52% for 600 mg, − 48% for 300 mg,
− 36% for 150 mg (600 mg vs. 150 mg: p < 0.05, 600 mg vs. 300 mg: p = NS)
All treatments vs. placebo: p < 0.001
  1. Notes: The comparsions included aliskiren versus placebo, aliskiren versus ARBs and ACEIs.
  2. Abbreviations: UAER Urinary Albumin Excretion Ratio, UPCR Urinary Protein Creatinine Rate, UPER Urinary Protein Excretion Rate